REVIEW article
Front. Pharmacol.
Sec. Ethnopharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1602563
Shufeng Jiedu Capsules for treating wind-heat syndrome respiratory diseases: A systematic review and meta-analysis
Provisionally accepted
- 1Henan University of Traditional Chinese Medicine, Zhengzhou, China
- 2Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: This study systematically evaluates the efficacy and safety of Shufeng Jiedu Capsules (SFJDC) for respiratory diseases with wind-heat syndrome, to support clinical practice and novel drug development based on syndrome-specific disease management. Methods: Randomized controlled trials (RCTs) on SFJDC for wind-heat syndrome respiratory diseases were searched across multiple databases and registries until December 2024. Study selection, data extraction, and risk of bias assessment were conducted independently. Meta-analysis was performed using RevMan 5.3 and Stata 18; evidence quality was graded with the GRADE approach. Results: Twenty-five RCTs comprising 2681 patients were included. The overall evidence certainty was low or very low due to methodological limitations. SFJDC combined with biomedicine significantly improved TCM syndrome response rate (RR = 1.17, P < 0.00001) and shortened cough resolution (MD = -0.97, P < 0.00001) with high certainty. Moderate-certainty evidence supported improved imaging absorption (RR = 1.15, P = 0.0009) and rales resolution (MD = -1.48, P = 0.04). Benefits in clinical effectiveness, fever resolution, CRP, and PCT had low or very low certainty. No significant difference in adverse events was observed (RR = 0.88, P = 0.80); all were mild and controllable. Conclusions: SFJDC combined with biomedicine may provide benefits in wind-heat syndrome respiratory diseases with a favorable safety profile. However, conclusions are limited by the low evidence certainty. High-quality trials are warranted for validation.
Keywords: Shufeng Jiedu Capsules, Wind-heat syndrome, Respiratory diseases, randomized controlled trials, Meta-analysis
Received: 29 Mar 2025; Accepted: 05 Sep 2025.
Copyright: © 2025 Liu, Wang, Zhao and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hailong Zhang, Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.